company background image
A145020 logo

Hugel KOSDAQ:A145020 Stock Report

Last Price

₩253.00k

Market Cap

₩2.8t

7D

4.8%

1Y

82.9%

Updated

09 Oct, 2024

Data

Company Financials +

A145020 Stock Overview

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Hugel, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hugel
Historical stock prices
Current Share Price₩253,000.00
52 Week High₩295,500.00
52 Week Low₩131,600.00
Beta0.60
11 Month Change2.02%
3 Month Change12.95%
1 Year Change82.94%
33 Year Change48.91%
5 Year Change100.21%
Change since IPO350.98%

Recent News & Updates

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Sep 13
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Aug 09
There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Recent updates

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Sep 13
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Aug 09
There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Jun 10
Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Apr 19
Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29
Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Mar 05
Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Mar 04
Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

Mar 19
Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Feb 25
What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Feb 04
Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Jan 17
The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29
Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

Dec 14
Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Nov 24
How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Shareholder Returns

A145020KR BiotechsKR Market
7D4.8%2.1%0.3%
1Y82.9%45.8%6.4%

Return vs Industry: A145020 exceeded the KR Biotechs industry which returned 45.8% over the past year.

Return vs Market: A145020 exceeded the KR Market which returned 6.4% over the past year.

Price Volatility

Is A145020's price volatile compared to industry and market?
A145020 volatility
A145020 Average Weekly Movement8.5%
Biotechs Industry Average Movement9.0%
Market Average Movement6.8%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A145020 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A145020's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001594Ji-hoon Sohnwww.hugel.co.kr

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name.

Hugel, Inc. Fundamentals Summary

How do Hugel's earnings and revenue compare to its market cap?
A145020 fundamental statistics
Market cap₩2.78t
Earnings (TTM)₩111.17b
Revenue (TTM)₩343.49b

25.0x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A145020 income statement (TTM)
Revenue₩343.49b
Cost of Revenue₩81.70b
Gross Profit₩261.80b
Other Expenses₩150.62b
Earnings₩111.17b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)10.13k
Gross Margin76.22%
Net Profit Margin32.37%
Debt/Equity Ratio2.9%

How did A145020 perform over the long term?

See historical performance and comparison